Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIST Milestone Pharmaceuticals Inc.

Closed 12-18 16:00:00 EST

2.08

-0.07

-3.26%

盘后2.08

+0.000.00%

19:59 EST

High2.22	Low2.05	Vol4.92M
Open2.19	D1 Closing2.15	Amplitude7.91%
Mkt Cap177.15M	Tradable Cap163.93M	Total Shares85.17M
T/O10.42M	T/O Rate6.24%	Tradable Shares78.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIST","market":"US","secType":"STK","nameCN":"Milestone Pharmaceuticals Inc.","latestPrice":2.08,"timestamp":1766091600000,"preClose":2.15,"halted":0,"volume":4919116,"hourTrading":{"tag":"盘后","latestPrice":2.08,"preClose":2.08,"latestTime":"19:59 EST","volume":76137,"amount":157645.8416,"timestamp":1766105992774},"delay":0,"floatShares":78814500,"shares":85169344,"eps":-0.784567,"marketStatus":"Closed","change":-0.07,"latestTime":"12-18 16:00:00 EST","open":2.185,"high":2.22,"low":2.05,"amount":10420547.113847999,"amplitude":0.07907,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.784567,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":2.15,"preHourTrading":{"tag":"盘前","latestPrice":2.19,"preClose":2.15,"latestTime":"09:29 EST","volume":100655,"amount":216823.75384,"timestamp":1766068199999},"postHourTrading":{"tag":"盘后","latestPrice":2.08,"preClose":2.08,"latestTime":"19:59 EST","volume":76137,"amount":157645.8416,"timestamp":1766105992774},"volumeRatio":0.182956,"impliedVol":1.2265,"impliedVolPercentile":0.324},"requestUrl":"/m/hq/s/MIST/tweets","defaultTab":"tweets","newsList":[{"id":"2592946868","title":"AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2592946868","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592946868?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:00","pubTimestamp":1766008827,"startTime":"0","endTime":"0","summary":"AptarGroup Inc. announced that its Bidose  Liquid Nasal Spray System has been selected as the delivery mechanism for CARDAMYST  Nasal Spray, which has received approval from the U.S. Food and Drug Administration  for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia  in adults. The approval marks a collaboration between AptarGroup Inc. and Milestone Pharmaceuticals Inc., the developer of CARDAMYST, and highlights Aptar's expanding role in providing innovative drug delivery solutions for new therapeutic areas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire  on December 17, 2025, and is solely responsible","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL7QDrpY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4126","ATR","MIST"],"gpt_icon":0},{"id":"2591134626","title":"BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2591134626","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591134626?lang=en_us&edition=fundamental","pubTime":"2025-12-16 02:44","pubTimestamp":1765824246,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, NvidiaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4N3XL10S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LYB","VNDA","TPL","KLAC","CRBG","CPB","MOS","BMY","CDE","ZTS","SNVD.UK","AMAT","NVDA","APA","ALB","NOW","SPOT","SCCO","IMNM","TXN","LNG","NVIW.SI","DG","LRCX","XOM","KYTX","FAST","NCLH","JBL","FCX","NEM","MIST","LAZR","NVDX","NVDU","CNX","INGM","3NVD.UK","FMC","CVX","APD","ENTG","HL","NVDS.UK"],"gpt_icon":1},{"id":"2591628670","title":"Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591628670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591628670?lang=en_us&edition=fundamental","pubTime":"2025-12-16 00:06","pubTimestamp":1765814760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 11:06 ET (16:06 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2591628816","title":"BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, Zillow","url":"https://stock-news.laohu8.com/highlight/detail?id=2591628816","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591628816?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:53","pubTimestamp":1765814010,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, ZillowEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL0UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNX","ZTS","LU1992135399.USD","KYTX","LRCX","LNG","INGM","LU1720051108.HKD","LU0654597011.USD","NOW","LU2357125470.USD","CRBG","FMC","FCX","MIST","TSYW.SI","LU0048573561.USD","LU0053666078.USD","LU0648000940.SGD","FAST","APD","HL","VNDA","LU1923622614.USD","LU1223083913.SGD","IE0034235303.USD","LU0353189763.USD","KLAC","LYB","LU0889565833.HKD","LU0630314457.HKD","IMNM","LU0708995401.HKD","SCCO","ALB","NEM","LU1823568750.SGD","CDE","DG","LU1861214812.USD","NCLH","LU1989773731.SGD","LU0072463663.USD","AMAT","JBL"],"gpt_icon":1},{"id":"2591647792","title":"Milestone Pharmaceuticals Inc : TD Cowen Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647792?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:10","pubTimestamp":1765811402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2591642708","title":"Milestone Pharmaceuticals Inc. : H.c. Wainwright Raises Target Price to $8 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591642708?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:44","pubTimestamp":1765809860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nAZN4RF5A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2591774644","title":"BUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Carvana, ServiceNow","url":"https://stock-news.laohu8.com/highlight/detail?id=2591774644","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591774644?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:18","pubTimestamp":1765808318,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Carvana, ServiceNowEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL0MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FCX","IMNM","LU1153585028.USD","AMAT","SCCO","IE00B7SZLL34.SGD","LU1551013342.USD","LU0640476718.USD","LYB","IE00BZ9MQY76.HKD","BK4564","BK4551","LRCX","BK4550","IE0034235303.USD","DG","LU1223082196.USD","LU2290526834.HKD","ZTS","LU0011850046.USD","LU2237443382.USD","CVNA","FAST","IE0009356076.USD","IE00BJJMRY28.SGD","APD","LU1989763005.USD","HL","NOW","LU0256863811.USD","LU2360106780.USD","NCLH","LU0265550946.USD","FMC","MU","LU0158827948.USD","LU2931357623.SGD","NVMI","AU","LU2125909916.SGD","MIST","NEM","LU1778281490.HKD","CRBG","CDE","KYTX","KLAC"],"gpt_icon":1},{"id":"2591649179","title":"Shares of Milestone Pharmaceuticals up 34.8% Premarket After FDA Approves Co's Heart Rhythm Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649179?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:05","pubTimestamp":1765803928,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XK05D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2591648798","title":"Milestone Pharmaceuticals Says US FDA Approves Cardamyst Spray for Supraventricular Tachycardia Episodes","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648798","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591648798?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:17","pubTimestamp":1765797428,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals  said Friday that the US Food and Drug Administration has approved its Cardamyst nasal spray for the conversion of acute episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults.This approval means 2 million Americans with paroxysmal supraventricular tachycardia can have access to the potentially self-administered treatment, the company said.The drug will be available in pharmacies in Q1 2026.The approval followed a clinical trial program involving 1,800 participants and 2,000 episodes of paroxysmal supraventricular tachycardia, which showed benefits for 73% of patients after 60 minutes, the company said.Paroxysmal supraventricular tachycardia results in episodes of fast heart rates, the company said.Shares of the company were down 18% in recent premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2591068041","title":"FDA Approves Milestone Pharmaceuticals’ CARDAMYST Nasal Spray for PSVT","url":"https://stock-news.laohu8.com/highlight/detail?id=2591068041","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591068041?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:00","pubTimestamp":1765587622,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals Inc. has received FDA approval for CARDAMYST  nasal spray, marking the first self-administered treatment for adults with paroxysmal supraventricular tachycardia . This is the first FDA-approved treatment for PSVT in over 30 years, offering more than two million Americans a rapid-acting option that can be used outside of healthcare settings. The approval is supported by robust clinical data, including the successful Phase 3 RAPID trial. CARDAMYST is expected to be available in retail pharmacies in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 13, 2025, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nNDL6wl3Wr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","MIST","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","BK4588","SG9999014039.USD","BK4007","SG9999014005.SGD","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2591434680","title":"Milestone Receives FDA Approval of Cardamyst™ (Etripamil) as First and Only Self-Administered Nasal Spray for Adults With Paroxysmal Supraventricular Tachycardia (Psvt)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591434680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591434680?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:00","pubTimestamp":1765587600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nTUA87Z5GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2591688297","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:41 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2591688297","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591688297?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:41","pubTimestamp":1765557682,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:41 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nAQN2LDFOK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2582375915","title":"Milestone Pharma Q3 net loss widens on commercial expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375915","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375915?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:17","pubTimestamp":1762949820,"startTime":"0","endTime":"0","summary":"Milestone Pharma Q3 net loss widens on commercial expensesOverviewMilestone Q3 2025 reports no revenue, net loss of $11.9 mlnCompany prepares for CARDAMYST launch pending FDA approval in DecemberMiles","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2581864998","title":"Milestone Pharmaceuticals Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581864998","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581864998?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:11","pubTimestamp":1762524669,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals Inc  expected to post a loss of16cents a share - Earnings Preview Milestone Pharmaceuticals Inc MIST.OQ MIST.O is expected to  show no change in quarterly revenue when it rep","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1UM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2567118357","title":"Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA) and Milestone Pharmaceuticals (MIST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2567118357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567118357?lang=en_us&edition=fundamental","pubTime":"2025-09-15 17:50","pubTimestamp":1757929811,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kala Pharmaceuticals (KALA – Research Report) and Milestone Pharm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kala-pharmaceuticals-kala-and-milestone-pharmaceuticals-mist-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kala-pharmaceuticals-kala-and-milestone-pharmaceuticals-mist-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","HCSG","KALA","MIST","BK4007","BK4139"],"gpt_icon":0},{"id":"2566998041","title":"Milestone Pharmaceuticals Initiated at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2566998041","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566998041?lang=en_us&edition=fundamental","pubTime":"2025-09-11 20:07","pubTimestamp":1757592420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 11, 2025 08:07 ET (12:07 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST"],"gpt_icon":0},{"id":"2566448964","title":"Milestone Pharmaceuticals, Inc. : Wells Fargo Initiates Coverage With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2566448964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566448964?lang=en_us&edition=fundamental","pubTime":"2025-09-11 18:39","pubTimestamp":1757587148,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nAZN4I4NEZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2566616789","title":"Wells Fargo Initiates Milestone Pharmaceuticals at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2566616789","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566616789?lang=en_us&edition=fundamental","pubTime":"2025-09-11 18:09","pubTimestamp":1757585356,"startTime":"0","endTime":"0","summary":"Wells Fargo Initiates Milestone Pharmaceuticals at Overweight","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIST"],"gpt_icon":0},{"id":"2558764970","title":"Milestone Pharmaceuticals Q2 EPS $(0.20) Misses $(0.17) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558764970","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558764970?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:15","pubTimestamp":1754997337,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 42.86 percent decrease over losses of $(0.14) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47054665/milestone-pharmaceuticals-q2-eps-0-20-misses-0-17-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST"],"gpt_icon":0},{"id":"2558649447","title":"Milestone Pharmaceuticals Q2 Income From Operations USD -12.531 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649447?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:05","pubTimestamp":1754996747,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nPLXB638B6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.milestonepharma.com","stockEarnings":[{"period":"1week","weight":-0.1948},{"period":"1month","weight":-0.0733},{"period":"3month","weight":0.1026},{"period":"6month","weight":0.2722},{"period":"1year","weight":0.1813},{"period":"ytd","weight":-0.089}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.042562},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.118335},{"month":3,"riseRate":0.5,"avgChangeRate":-0.166289},{"month":4,"riseRate":0.666667,"avgChangeRate":0.196115},{"month":5,"riseRate":0.666667,"avgChangeRate":0.024602},{"month":6,"riseRate":0.571429,"avgChangeRate":0.044863},{"month":7,"riseRate":0.714286,"avgChangeRate":0.159669},{"month":8,"riseRate":0.571429,"avgChangeRate":0.085263},{"month":9,"riseRate":0.571429,"avgChangeRate":0.012421},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.130693},{"month":11,"riseRate":0.571429,"avgChangeRate":0.153201},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.080262}],"exchange":"NASDAQ","name":"Milestone Pharmaceuticals Inc.","nameEN":"Milestone Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Milestone Pharmaceuticals Inc.(MIST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Milestone Pharmaceuticals Inc.,MIST,Milestone Pharmaceuticals Inc.股票,Milestone Pharmaceuticals Inc.股票老虎,Milestone Pharmaceuticals Inc.股票老虎国际,Milestone Pharmaceuticals Inc.行情,Milestone Pharmaceuticals Inc.股票行情,Milestone Pharmaceuticals Inc.股价,Milestone Pharmaceuticals Inc.股市,Milestone Pharmaceuticals Inc.股票价格,Milestone Pharmaceuticals Inc.股票交易,Milestone Pharmaceuticals Inc.股票购买,Milestone Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Milestone Pharmaceuticals Inc.(MIST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction